Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 0.81% and Operating profit at -8.36% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.33
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CAD 439 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.35
32.50%
-10.91
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
242.97%
0%
242.97%
6 Months
190.72%
0%
190.72%
1 Year
234.21%
0%
234.21%
2 Years
521.06%
0%
521.06%
3 Years
326.32%
0%
326.32%
4 Years
699.24%
0%
699.24%
5 Years
98.44%
0%
98.44%
Spectral Medical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.81%
EBIT Growth (5y)
-8.36%
EBIT to Interest (avg)
-8.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
-0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-10.14
EV to EBIT
-35.63
EV to EBITDA
-36.37
EV to Capital Employed
-16.17
EV to Sales
166.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.80
0.50
60.00%
Operating Profit (PBDIT) excl Other Income
-2.40
-4.00
40.00%
Interest
1.20
1.20
Exceptional Items
-2.90
0.90
-422.22%
Consolidate Net Profit
-1.90
-4.40
56.82%
Operating Profit Margin (Excl OI)
-3,068.90%
-8,700.60%
563.17%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 60.00% vs 66.67% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 56.82% vs -10.00% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2.30
1.60
43.75%
Operating Profit (PBDIT) excl Other Income
-11.70
-11.20
-4.46%
Interest
3.20
1.30
146.15%
Exceptional Items
2.50
-2.20
213.64%
Consolidate Net Profit
-15.40
-15.50
0.65%
Operating Profit Margin (Excl OI)
-5,248.00%
-7,147.10%
189.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 43.75% vs -5.88% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 0.65% vs -103.95% in Dec 2023
About Spectral Medical, Inc. 
Spectral Medical, Inc.
Pharmaceuticals & Biotechnology
Spectral Medical Inc. is a late stage theranostic company advancing therapeutic options for sepsis and septic shock. The Company has developed a product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA). The EAA is a rapid in-vitro diagnostic test that measures negative bacterial cell wall (endotoxin) activity in a whole blood sample. The Company, through its wholly owned subsidiary, Dialco Medical Inc. (Dialco), is also commercializing a new platform, SAMI. Its platform is targeting the renal replacement therapy (RRT) market.
Company Coordinates 
Company Details
135 - 2 The West Mall , TORONTO ON : M9C 1C2
Registrar Details






